- 2002: Identified the possible pivotal toxin in Alzheimer’s Disease.
- 2004: Identified the target of the toxin.
- 2004 – 2012: Characterised bioactivity of toxin and designed blocker.
- 2013: Negotiated with University, IP assigned Neuro-Bio
Company Development 2013 – 2017
Formed the company and attracted initial seed investment.
Filed patent application on chemical copostition of matter for neuro-protection.
Attracted angel funding, recruited scientific team and established own labs.
Filed patent on biomarker and identified direct link with Alzheimer’s.
Attracted Series A funding, recruited management team and identified drug and biomarker development partners.